Science ❯Medicine

Drug Development

Targeted Therapy Clinical Research

Vertex Halts VX-993 Acute Pain Program After Phase 2 Trial Failure

The biotech will shift focus to a Phase 3 study of Journavx in diabetic neuropathy following the failed VX-993 trial.

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research